KIRKLAND, Wash.--(BUSINESS WIRE)--Amcyte Pharma, a Seattle-based company dedicated to the development of novel pharmaceutical products in immunology, announced the U.S. launch of its Nasitrol® nasal spray for sinus irrigation. In an independent clinical trial published in the peer-reviewed International Journal of General Medicine, Nasitrol reduced COVID transmission among ICU staff by nearly 80%, suggesting it could represent a safe and effective prophylaxis to prevent transmission of COVID-19.